Lower levels of the FMRP protein in neural stem cells delay their conversion into neurons during brain development by…
Articles by José Lopes, PhD
Treatment with the Alzheimer’s therapy donepezil reduced brain activation in response to a gaze stimulus, but did not directly…
Anxiety, learning difficulties, and behavior problems are the main areas of concern in patients with fragile X syndrome (FXS),…
A greater ability to generate words, phrases and sentences correlates with lower autism spectrum disorder (ASD) symptom severity in adolescent and…
Mavoglurant is safe and well-tolerated in the long-term to treat adolescents and adults who have fragile X symptoms. The investigational…
Altered calcium levels and poorly regulated activity in specific calcium channels in nerve cells could underlie fragile X syndrome (FXS)…
High levels of a pro-inflammatory molecule called interleukin (IL)-6 in the brain could be key to abnormal neuronal communication in…
A University of Calgary team attempting to reverse symptoms of fragile X syndrome (FXS) in mice was awarded a…
The U.S. Food and Drug Administration (FDA) recently granted fast track designation to Ovid Therapeutics’ Fragile X syndrome…
Zynerba Pharmaceuticals will start a clinical trial of its cannabis-based Fragile X syndrome treatment ZYN002 in mid-2018. The U.S. Food…